IceCure Medical Statistics
Total Valuation
IceCure Medical has a market cap or net worth of $70.41 million. The enterprise value is $63.79 million.
Important Dates
The next estimated earnings date is Tuesday, August 19, 2025, before market open.
| Earnings Date | Aug 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IceCure Medical has 68.70 million shares outstanding. The number of shares has increased by 16.74% in one year.
| Current Share Class | 68.70M |
| Shares Outstanding | 68.70M |
| Shares Change (YoY) | +16.74% |
| Shares Change (QoQ) | +2.92% |
| Owned by Insiders (%) | 40.58% |
| Owned by Institutions (%) | 0.19% |
| Float | 40.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.54 |
| Forward PS | 15.58 |
| PB Ratio | 9.87 |
| P/TBV Ratio | 11.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 19.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.89 |
| Quick Ratio | 1.27 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -173.47% and return on invested capital (ROIC) is -105.73%.
| Return on Equity (ROE) | -173.47% |
| Return on Assets (ROA) | -72.28% |
| Return on Invested Capital (ROIC) | -105.73% |
| Return on Capital Employed (ROCE) | -257.09% |
| Revenue Per Employee | $49,591 |
| Profits Per Employee | -$231,773 |
| Employee Count | 66 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0.90 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.69% in the last 52 weeks. The beta is 2.51, so IceCure Medical's price volatility has been higher than the market average.
| Beta (5Y) | 2.51 |
| 52-Week Price Change | +34.69% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 47.87 |
| Average Volume (20 Days) | 397,600 |
Short Selling Information
The latest short interest is 237,853, so 0.35% of the outstanding shares have been sold short.
| Short Interest | 237,853 |
| Short Previous Month | 206,073 |
| Short % of Shares Out | 0.35% |
| Short % of Float | 0.58% |
| Short Ratio (days to cover) | 0.93 |
Income Statement
In the last 12 months, IceCure Medical had revenue of $3.27 million and -$15.30 million in losses. Loss per share was -$0.29.
| Revenue | 3.27M |
| Gross Profit | 1.40M |
| Operating Income | -15.70M |
| Pretax Income | -14.49M |
| Net Income | -15.30M |
| EBITDA | -15.37M |
| EBIT | -15.70M |
| Loss Per Share | -$0.29 |
Full Income StatementBalance Sheet
The company has $6.04 million in cash and $380,000 in debt, giving a net cash position of $5.66 million or $0.08 per share.
| Cash & Cash Equivalents | 6.04M |
| Total Debt | 380,000 |
| Net Cash | 5.66M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | 6.00M |
| Book Value Per Share | 0.10 |
| Working Capital | 4.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.75 million and capital expenditures -$49,000, giving a free cash flow of -$13.80 million.
| Operating Cash Flow | -13.75M |
| Capital Expenditures | -49,000 |
| Free Cash Flow | -13.80M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
| Gross Margin | 42.77% |
| Operating Margin | -479.77% |
| Pretax Margin | -467.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IceCure Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.74% |
| Shareholder Yield | -16.74% |
| Earnings Yield | -22.03% |
| FCF Yield | -19.87% |
Analyst Forecast
The average price target for IceCure Medical is $2.50, which is 143.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.50 |
| Price Target Difference | 143.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 93.21% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IceCure Medical has an Altman Z-Score of -11.93 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.93 |
| Piotroski F-Score | 3 |
